Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm
It is not uncommon for a large company to want to expand its reach internationally and this is typically done by partnering with companies to test the water or establishing a satellite office and then getting to work on some projects. However, a major Chinese pharma is going all in.
Jiangsu Hengrui has launched Luzsana Biotechnology to serve as an arm to develop and deliver therapeutics outside of the Chinese market. Serving as a wholly owned subsidiary of Hengrui Pharma, Luzsana will be provided Hengrui’s pipeline of programs, spanning over 250 clinical studies, to develop and eventually commercialize.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.